Ergoteles’s Regenxbio RGNX Stock Holding History

Ergoteles’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-19,016	Closed	-$380K	–	667
2023 Q2	$380K	Buy	19,016 +3,934	+26%	+$75.8K	0.02%	713
2023 Q1	$285K	Buy	+15,082	New	+$334K	0.01%	915
2021 Q3	–	Sell	-7,400	Closed	-$287K	–	1597
2021 Q2	$287K	Buy	+7,400	New	+$265K	0.01%	1096

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Ergoteles's RGNX Position: Q3 2023 in Review

Ergoteles sold out of Regenxbio (RGNX) in Q3 2023, closing a stake of 19,016 shares — an estimated $380K sold.

Ergoteles first reported a position in RGNX in Q2 2021 and held it in 3 quarters. The position peaked at $380K in Q2 2023. 159 funds tracked by Wall St. Rank hold RGNX as of Q3 2023.

Ergoteles reported no remaining Regenxbio position as of Q3 2023 after selling out during the quarter.
Ergoteles sold 19,016 Regenxbio shares in Q3 2023, an estimated $380K.
Ergoteles first reported a position in Regenxbio in Q2 2021 and held it in 3 quarters.
Ergoteles's Regenxbio position peaked at $380K in Q2 2023.
159 funds tracked by Wall St. Rank held Regenxbio as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.